Biotech's Patent Suite Catches Sparks From Federal Circuit's Prometheus Decision
Executive Summary
Pharmaceutical and biotech firms will have broader patent protection after an appeals court drew a narrow definition of what constitutes a natural phenomenon in the biotech arena. Specifically, the court ruled that a test to measure a drug's metabolites in order to determine the proper drug dosage is patentable subject matter
You may also be interested in...
Supreme Court Overturns Drug Calibration Patents, Creating Confusion In Biotech Realm
The court’s finding that Prometheus’ drug calibration test is unpatentable has left the biotech community reeling with uncertainty as to whether method of treatment claims, particularly those involving biomarkers, will be patent eligible.
Biotech Building Blocks On Trial: ACLU, Myriad Battle Over BRCA Cancer Gene Patents
ACLU argues that isolated DNA molecules are like a carburetor taken from an engine, the same inside as outside the body; Myriad says they are new compositions of matter.
Biotech Building Blocks On Trial: ACLU, Myriad Battle Over BRCA Cancer Gene Patents
ACLU argues that isolated DNA molecules are like a carburetor taken from an engine, the same inside as outside the body; Myriad says they are new compositions of matter.